Modality
Radioligand
MOA
SGLT2i
Target
CD47
Pathway
Complement
NMOSD
Development Pipeline
Preclinical
~Aug 2014
→ ~Nov 2015
Phase 1
~Feb 2016
→ ~May 2017
Phase 2
Aug 2017
→ Nov 2030
Phase 2Current
NCT04166964
671 pts·NMOSD
2020-11→2030-11·Active
NCT06000602
342 pts·NMOSD
2017-08→2030-04·Active
1,013 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-03-162w agoPDUFA· NMOSD
2030-04-064.0y awayPh3 Readout· NMOSD
2030-11-174.6y awayPh3 Readout· NMOSD
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Active
P2/3
Active
Catalysts
PDUFA
2026-03-16 · 2w ago
NMOSD
Ph3 Readout
2030-04-06 · 4.0y away
NMOSD
Ph3 Readout
2030-11-17 · 4.6y away
NMOSD
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04166964 | Phase 2/3 | NMOSD | Active | 671 | EDSS |
| NCT06000602 | Phase 2/3 | NMOSD | Active | 342 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| BMR-1165 | BioMarin | Phase 2 | CD47 |